Clinical trial · Observational
A Study to Assess Prevalence of a Specific Protein Overexpression in Adult Participants With Non-Small Cell Lung Cancer
International Real-World Study of MET Overexpression in Patients With Non-Small Cell Lung Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for 80%-85% of lung cancers cases of which 60% are non-squamous (NSQ). This study will evaluate the prevalence of mesenchymal epithelial transition (MET) overexpression (OE) in adult participants with advanced or metastatic NSQ NSCLC. Archived tissue biopsies will be tested for MET OE and data from approximately 500 participants will be collected. No participants will be enrolled in this study. Participants' charts will be reviewed. No drug will be administered as a part of this study. The duration of the study will be approximately 15 months. There is no additional burden for participants in this trial.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (1)
- label
- Participants Undergoing Chart Review
- description
- Participants treated for non small cell lung cancer undergoing chart review and retrospective mesenchymal epithelial transition (MET) overexpression (OE) testing of tissue biopsies.
Primary outcomes (1)
- measure
- Presence of Mesenchymal Epithelial Transition (MET) protein overexpression (OE)
- timeFrame
- Up to 15 Months
- description
- OE is defined as: positive: \>= 25% of tumor cells with 3+ staining intensity, or negative: \< 25% of tumor cells with 3+ staining intensity. High overexpression (OE high) is defined as: positive: \>= 50% of tumor cells with 3+ staining intensity negative: \< 50% of tumor cells with 3+ staining intensity. These are determined by an immunohistochemistry (IHC) performed by the local laboratory.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Previously consented and/or prospective collection of consent for research use of banked biological materials and clinical data. * Confirmed advanced and/or metastatic non-squamous (NSQ) non-small cell lung cancer (NSCLC). * Has formalin-fixed paraffin-embedded (FFPE) tissue collected since 2019. Exclusion Criteria: * Specimens collected before 2019. * Insufficient specimen tissue for testing. * Insufficient specimen quality (e.g., not 4-5 µm in thickness) which precludes testing. * Adenosquamous and sarcomatous histologies of NSCLC.
References
Publications (0)
Data not yet available